Summit Therapeutics Inc. SMMT
We take great care to ensure that the data presented and summarized in this overview for Summit Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SMMT
View all-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.13MShares$57.1 Million0.0% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.16MShares$39.5 Million0.05% of portfolio
-
Morgan Stanley New York, NY1.93MShares$35.1 Million0.0% of portfolio
-
Apeiron Capital LTD1.31MShares$23.9 Million30.03% of portfolio
-
Ubs Group Ag1.28MShares$23.3 Million0.0% of portfolio
Latest Institutional Activity in SMMT
Top Purchases
Top Sells
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Insider Transactions at SMMT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 21
2025
|
Yu Xia Director |
BUY
Open market or private purchase
|
Indirect |
533,617
+1.64%
|
$9,605,106
$18.74 P/Share
|
|
Oct 21
2025
|
Manmeet Singh Soni COO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
53,361
+1.71%
|
$960,498
$18.74 P/Share
|
|
Oct 21
2025
|
Bhaskar Anand Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,680
+14.31%
|
$480,240
$18.74 P/Share
|
|
Oct 21
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
14,247,597
+1.71%
|
$256,456,746
$18.74 P/Share
|
|
Oct 21
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
26,680
+25.81%
|
$480,240
$18.74 P/Share
|
|
Oct 21
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
26,680
+25.81%
|
$480,240
$18.74 P/Share
|
|
Oct 21
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
266,808
+1.03%
|
$4,802,544
$18.74 P/Share
|
|
Oct 21
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,980,789
+2.39%
|
$251,654,202
$18.74 P/Share
|
|
Sep 11
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.0%
|
$90,000
$18.07 P/Share
|
|
Sep 11
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.0%
|
$90,000
$18.07 P/Share
|
|
Sep 10
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
333,394
+0.06%
|
$5,667,698
$17.68 P/Share
|
|
Sep 10
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
333,394
+0.06%
|
$5,667,698
$17.68 P/Share
|
|
May 30
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
74,545
+0.01%
|
$149,090
$2.64 P/Share
|
|
May 30
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
74,545
+0.01%
|
$149,090
$2.64 P/Share
|
|
Apr 08
2025
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
3,985,055
+0.71%
|
$3,985,055
$1.58 P/Share
|
|
Apr 08
2025
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
3,985,055
+0.71%
|
$3,985,055
$1.58 P/Share
|
|
Oct 03
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
315,681
+3.0%
|
$315,681
$1.58 P/Share
|
|
Sep 11
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
44,052
+0.18%
|
$969,144
$22.7 P/Share
|
|
Sep 11
2024
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,325,991
+0.6%
|
$73,171,802
$22.7 P/Share
|
|
Sep 11
2024
|
Jeff Huber Director |
BUY
Grant, award, or other acquisition
|
Indirect |
44,052
+50.0%
|
$969,144
$22.7 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 28.6M shares |
|---|---|
| Exercise of conversion of derivative security | 149K shares |
| Open market or private purchase | 1.26M shares |
| Exercise of in-the-money or at-the-money derivatives securities | 7.97M shares |